氨磷汀联合化疗治疗卵巢癌的临床疗效及对患者血清肿瘤标志物、预后的影响

Clinical Curative Effect of Amifostine Combined with Chemotherapy on Ovarian Cancer and Its Influences on Serum Tumor Markers and Prognosis of Patients

目的观察氨磷汀联合化疗治疗卵巢癌的临床疗效及对患者血清肿瘤标志物、预后的影响。方法选取120例卵巢癌患者,按随机数表法分为2组,对照组60例给予紫杉醇^(+)卡铂化疗治疗,实验组60例在对照组基础上联合氨磷汀治疗。比较2组临床疗效、血清肿瘤标志物、T淋巴细胞亚群水平,毒副作用发生情况及预后情况。结果化疗结束后,实验组疾病控制率为91.67%,高于对照组的83.33%,差异无统计学意义(P>0.05)。治疗后,2组辅助/诱导T淋巴细胞(CD4^(+))、CD4^(+)/CD8^(+)水平均低于治疗前,抑制/细胞毒T淋巴细胞(CD8^(+))水平高于治疗前;其中,实验组的CD4^(+)/CD8^(+)水平高于对照组,差异有统计学意义(P<0.05)。治疗后,2组腺癌相关抗原(CA153)、卵巢癌相关抗原(CA125)、癌胚抗原(CEA)水平均低于治疗前;其中,实验组血清CEA水平低于对照组,差异有统计学意义(P<0.05)。2组骨髓抑制、周围神经毒性反应发生率比较,差异有统计学意义(P<0.05)。实验组1年生存率为80.00%(48/60),高于对照组的75.00%(45/60),但差异无统计学意义(P>0.05)。结论氨磷汀联合化疗可显著改善卵巢癌患者血清CEA水平及CD4^(+)/CD8^(+)水平,降低化疗不良反应,对患者近期疗效、1年生存率无明显影响。

Objective To observe the clinical curative effect of amifostine combined with chemotherapy on ovarian cancer and its influences on serum tumor markers and prognosis of patients.Methods A total of 120 patients with ovarian cancer were enrolled and divided into the control group(paclitaxel and carboplatin chemotherapy)and the experimental group(amifostine treatment on basis of control group)by random number table method,60 cases in each group.The clinical curative effect,levels of serum tumor markers and T lymphocyte subsets,occurrence of side effects and prognosis were compared between the two groups.Results At the end of chemotherapy,the disease control rate in the experimental group was higher than that in the control group(91.67%vs 83.33%)(P>0.05).After treatment,levels of helper/induced T lymphocytes(CD4^(+))and CD4^(+)/CD8^(+)were decreased,while levels of inhibitory/cytotoxic T lymphocytes(CD8^(+))were increased in both groups.The level of CD4^(+)/CD8^(+)in the experimental group was higher than that in the control group(P<0.05).After treatment,levels of adenocarcinoma-associated antigen(CA153),ovarian cancer-associated antigen(CA125)and carcinoembryonic antigen(CEA)were decreased in both groups.The level of serum CEA in experimental group was lower than that in control group(P<0.05).There were significant differences in the incidence of bone marrow suppression and peripheral neurotoxicity between the two groups(P<0.05).The 1-year survival rate in experimental group was higher than that in control group[80.00%(48/60)vs 75.00%(45/60)](P>0.05).Conclusion Amifostine combined with chemotherapy can significantly improve levels of serum CEA and CD4^(+)/CD8^(+)in patients with ovarian cancer,and reduce adverse reactions of chemotherapy,without significant effects on short-term curative effect and 1-year survival rate.